Mass spectrometry in clinical proteomics - from the present to the future

被引:65
|
作者
Palmblad, Magnus [3 ]
Tiss, Ali [1 ,2 ]
Cramer, Rainer [1 ,2 ]
机构
[1] Univ Reading, Bioctr, Reading RG6 6AS, Berks, England
[2] Univ Reading, Dept Chem, Reading RG6 6AS, Berks, England
[3] Leiden Univ, Biomol Mass Sepctrometry Unit, Dept Parasitol, Med Ctr, Leiden, Netherlands
关键词
Clinical proteomics; Diagnostics; Mass spectrometry; Profiling; Screening; LASER-DESORPTION/IONIZATION-TIME; NIPPLE ASPIRATE FLUID; SELDI-TOF-MS; PROTEIN IDENTIFICATION TECHNOLOGY; DIFFERENCE GEL-ELECTROPHORESIS; MALIGNANT MAMMOGRAPHIC LESIONS; SERUM PEPTIDOME PATTERNS; HUMAN PLASMA PROTEOME; BREAST-CANCER; OVARIAN-CANCER;
D O I
10.1002/prca.200800090
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
MS is an important analytical tool in clinical proteomics, primarily in the disease-specific discovery identification and characterisation of proteomic biomarkers and patterns. MS-based proteomics is increasingly used in clinical validation and diagnostic method development. The latter departs from the typical application of MS-based proteomics by exchanging some of the high performance of analysis for the throughput, robustness and simplicity required for clinical diagnostics. Although conventional MS-based proteomics has become an important field in clinical applications, some of the most recent MS technologies have not yet been extensively applied in clinical proteomics. in this review, we will describe the current state of MS in clinical proteomics and look to the future of this field.
引用
收藏
页码:6 / 17
页数:12
相关论文
共 50 条
  • [1] MALDI mass Spectrometry in proteomics; Past, present, and future
    Hillenkamp, F.
    [J]. MOLECULAR & CELLULAR PROTEOMICS, 2005, 4 (08) : S7 - S7
  • [2] Orbitrap mass spectrometry in proteomics: past, present and future
    Makarov, A. A.
    [J]. FEBS JOURNAL, 2013, 280 : 632 - 632
  • [3] Present and future perspectives on mass spectrometry for clinical microbiology
    Gant, Megan S.
    Chamot-Rooke, Julia
    [J]. MICROBES AND INFECTION, 2024, 26 (07)
  • [4] Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present
    Marcus Bantscheff
    Simone Lemeer
    Mikhail M. Savitski
    Bernhard Kuster
    [J]. Analytical and Bioanalytical Chemistry, 2012, 404 : 939 - 965
  • [5] Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present
    Bantscheff, Marcus
    Lemeer, Simone
    Savitski, Mikhail M.
    Kuster, Bernhard
    [J]. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2012, 404 (04) : 939 - 965
  • [6] Present possibilities and future development of clinical proteomics
    Lehmann, S.
    Dupuy, A.
    Peoch, K.
    Roche, S.
    Baudin, B.
    Quillard, M.
    Berger, F.
    Briand, G.
    Chwetzoff, S.
    Dine, G.
    Gonzalo, P.
    Dastugue, B.
    Seve, M.
    Siest, G.
    Beaudeux, J. -L.
    [J]. ANNALES DE BIOLOGIE CLINIQUE, 2007, 65 (05) : 463 - 471
  • [7] Mass spectrometry-based clinical proteomics profiling: current status and future directions
    Findeisen, Peter
    Neumaier, Michael
    [J]. EXPERT REVIEW OF PROTEOMICS, 2009, 6 (05) : 457 - 459
  • [8] Heart disease, clinical proteomics and mass spectrometry
    Stanley, BA
    Gundry, RL
    Cotter, RJ
    Van Eyk, JE
    [J]. DISEASE MARKERS, 2004, 20 (03) : 167 - 178
  • [9] Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold?
    Lehmann, Sylvain
    Brede, Cato
    Lescuyer, Pierre
    Cocho, Jose A.
    Vialaret, Jerome
    Bros, Pauline
    Delatour, Vincent
    Hirtz, Christophe
    [J]. CLINICA CHIMICA ACTA, 2017, 467 : 51 - 58
  • [10] Mass spectrometry-based clinical proteomics
    Pusch, W
    Flocco, MT
    Leung, SM
    Thiele, H
    Kostrzewa, M
    [J]. PHARMACOGENOMICS, 2003, 4 (04) : 463 - 476